CDN1163 – 10 mg

Brand:
Cayman
CAS:
892711-75-0
Storage:
-20
UN-No:
Non-Hazardous - /

CDN1163 is an allosteric activator of sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 2 (SERCA2) that enhances calcium uptake in endoplasmic reticulum (ER) vesicles when used at concentrations ranging from 1 to 10 µM.{57074} It decreases peroxide-induced cell death in HEK293 cells. CDN1163 (50 mg/kg) increases calcium uptake in ER microsomes isolated from obese mouse liver. It decreases blood glucose levels, plasma and hepatic triglyceride levels, and plasma cholesterol and malondialdehyde (MDA) levels in obese mice. CDN1163 (50 mg/kg) restores SERCA activity, prevents gastrocnemius muscle loss and contractile dysfunction, and reduces mitochondrial production of reactive oxygen species (ROS) in the CuZnSOD-deficient (Sod-/-) mouse model of oxidative stress-related muscle atrophy and weakness.{57075} It also improves motor deficits in the initiation time (IT), stepping, and cylinder tests for akinesia in a rat model of Parkinson’s disease induced by 6-OHDA (Item No. 25330).{57076}  

 

Available on backorder

SKU: 31123 - 10 mg Category:

Description

An allosteric activator of SERCA2; enhances calcium uptake in ER vesicles from 1-10 µM; decreases peroxide-induced cell death in HEK293 cells; increases calcium uptake in ER microsomes isolated from obese mouse liver at 50 mg/kg; decreases blood glucose levels, plasma and hepatic triglyceride levels, and plasma cholesterol and MDA levels in obese mice at 50 mg/kg; restores SERCA activity, prevents gastrocnemius muscle loss and contractile dysfunction, and reduces mitochondrial production of ROS in the Sod-/- mouse model of oxidative stress-related muscle atrophy and weakness; improves motor deficits in the IT, stepping, and cylinder tests for akinesia in a rat model of 6-OHDA-induced Parkinson’s disease


Formal name: 4-(1-methylethoxy)-N-(2-methyl-8-quinolinyl)-benzamide

Synonyms: 

Molecular weight: 320.4

CAS: 892711-75-0

Purity: ≥98%

Formulation: A solid